Olga Petrovna Sidorova

Dr. Olga Petrovna Sidorova


Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2002 in Neuropediatrics
Verified
Journal Article
Closed access
NBN. Barisic
N. Barisic
CSC. Schmidt
C. Schmidt
OSOlga Petrovna Sidorova
Olga Petrovna Sidorova
AHA. Herczegfalvi
A. Herczegfalvi
BGB. M. Gekht
B. M. Gekht
HLHanns Lochmüller
Hanns Lochmüller
Mutations in the ε-acetylcholine receptor (AChRε) subunit gene cause congenital myasthenic syndromes (CMS) with postsynaptic neural transmission defects. We present 3 male and 2 female patients from three unrelated Croatian, Hungarian, and Russian families with autosomal recessive CMS. All patients manifested with variable degrees of ophthalmoparesis and generalized, fatiguable muscle weakness since birth or early infancy. Electrophysiological studies showed a decremental response in all patients indicating a neuromuscular transmission defect. Pyridostigmine treatment improved the proximal muscle weakness whereas the ophthalmoparesis remained unchanged in all patients. Analysis of the AChRε subunit gene showed homozygosity for a novel splice site mutation of intron 7 ε(IVS7-2A/G) in the two Croatian siblings. ε-mRNA analysis by RT-PCR and direct sequencing revealed that exon 7 was spliced directly to exon 9 with skipping of exon 8. The Hungarian and Russian patients were heteroallelic carriers of the same mutation ε(IVS7-2A/G) and of a frameshifting mutation ε70insG and ε1293insG, respectively. We hypothesize that altered splice products may not be expressed as functional receptors at the cell surface. A haplotype analysis with polymorphic markers revealed a high degree of similarity for the ε(IVS7-2A/G) carrying allele in all families and may therefore indicate a common origin of the mutation. 1 Participation: NB and CS contributed equally

21 September 2022 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
OSOlga Petrovna Sidorova
Olga Petrovna Sidorova
AKA. S. Kotov
A. S. Kotov
MBM. S. Bunak
M. S. Bunak
YFYu. N. Filyushkin
Yu. N. Filyushkin
ЮФЮ. Н. Филюшкин
Ю. Н. Филюшкин
A new classification of limb‑girdle muscular dystrophy, which was adopted in 2018, is given. The reasons why there was a need to revise the classification are indicated. A new definition of this pathology is given. The diseases that were excluded from the new classification of limb‑girdle muscular dystrophy due to inconsistency with the new definition of this form of pathology are given. A comparison of the new and old classification of this group of muscular dystrophies is given. The genes responsible for the development of various forms of this pathology are indicated, as well as proteins of striated musculature, the synthesis of which is disrupted. It has been shown that a mutation in one gene can lead to different types of inheritance of limb‑girdle muscular dystrophy, which is important to take into account when conducting prenatal diagnostics. The new classification will allow introducing new forms of this pathology as new mutations in disease genes are detected.

1 January 2016 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
PDF file
SKS. V. Kotov
S. V. Kotov
OSOlga Petrovna Sidorova
Olga Petrovna Sidorova
Medical article медицинская статья

1 January 2006
Verified
Journal Article
Closed access
SKS V Kotov
S V Kotov
VNV Ia Neretin
V Ia Neretin
BAB V Agafonov
B V Agafonov
OSOlga Petrovna Sidorova
Olga Petrovna Sidorova

1 January 2022 in S.S. Korsakov Journal of Neurology and Psychiatry
Verified
Journal Article
Closed access
SKS.V. Kotov
S.V. Kotov
OSOlga Petrovna Sidorova
Olga Petrovna Sidorova
EBE.V. Borodataya
E.V. Borodataya
To evaluate the efficacy of the energotropic drug idebenon in hereditary neuromuscular pathology. A total of 9 patients with hereditary myopathies were examined during treatment with idebenone. Determination of muscle strength was carried out on the British medical research Council scale (0 points - no active movements, 5 points - no muscle weakness). The examination was performed before and 1 month after the start of treatment. Treatment regimen: idebenone was prescribed in a daily dose of 90 mg. In the general group of patients with hereditary ataxia, the median strength of the biceps muscle of the shoulder during treatment increased from 3.5 to 4.0 points (p>0.05). The median strength of the ilio-lumbar muscle increased from 3.0 to 4.0 points (p>0.05). Before treatment, the median number of sit-ups was 0, and after 1 month - 2 (p>0.05). We used the energotropic drug idebenon, a synthetic analog of the natural substance coenzyme Q10, which is involved in electron transfer in the mitochondrial respiratory chain complex III, for the treatment of patients with hereditary myopathies. In the general group of patients, there was an increase in muscle strength, although it did not reach statistical significance. Before the advent of energotropic drugs, the use of various methods of treating hereditary myopathies did not lead to an increase in muscle strength in patients. Therefore, the identified positive dynamics is of great importance in providing medical care to these patients and improving their quality of life.

1 January 2010
Verified
Journal Article
Closed access
GRG E Rudenskaia
G E Rudenskaia
ISI G Sermiagina
I G Sermiagina
SISergey Illarioshkin
Sergey Illarioshkin
OSOlga Petrovna Sidorova
Olga Petrovna Sidorova
VFV P Fedotov
V P Fedotov
APA V Poliakov
A V Poliakov